An open-label, multi-center phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer (ptc) positive for the BRAF V600 mutation and resistance to radioactive iodine (NCT01286753, No25530) - Brose, M; Cabanillas, M E; Cohen, E E (2013)
European Cancer Congress 2013